1. Introduction {#section0005}
===============

The etiology of lower respiratory tract infections (LRTIs) in adults, which are an important cause of morbidity, remains undetermined in more than 50% of cases ([@bib14], [@bib17], [@bib13]), mostly due to limited diagnostic procedures. The prevalence of respiratory viruses in adults is largely unexplored, as most relevant data concern infants and children ([@bib8], [@bib9], [@bib25], [@bib26], [@bib31], [@bib33]). Respiratory syncytial virus (RSV), parainfluenzaviruses (PIVs), influenzaviruses (FLUs) and adenoviruses (AdVs) are considered the leading causes of acute viral LRTIs ([@bib23], [@bib22], [@bib43], [@bib24]). However, many other respiratory viruses have been recently identified as possible causative agents of LRTIs. Human rhinoviruses (HRVs), which previously were believed to cause only mild upper respiratory illnesses, have been found in association with acute and chronic LRTIs, including asthma exacerbations and chronic obstructive pulmonary disease (COPD), although their role as causative agents has only been established for asthma ([@bib36], [@bib32], [@bib16], [@bib42]). Newly discovered viruses, such as human metapneumovirus (hMPV) and human coronaviruses (hCoVs) have been associated with LRTIs in children ([@bib39], [@bib15], [@bib40], [@bib8]).

The aim of this study was to assess the point prevalence of a full spectrum of respiratory viruses in the lower respiratory tract specimens of hospitalized adults by using a molecular diagnostic panel.

2. Methods {#section0010}
==========

A prospective collection of 510 lower respiratory samples from 433 adult patients with pulmonary diseases, admitted to three Italian hospitals was performed. Clinical-epidemiological data were collected through a standardized questionnaire. Patients with suspect *Mycobacterium tuberculosis* infection were not included in the analysis. The study was approved by the Institutional Ethics Committees, and informed consent signed by participants. The selection criterion for patients' enrolment was to have any one of the following samples sent to the laboratory for routine microbiological evaluation: sputum (SP), bronchoalveolar lavages (BALs), or endotracheal aspirate (EA). To minimize the possibility that positive results reflected contamination from the upper respiratory tract, only samples containing more than 25 polymorphonuclear leucocytes per field (40×) were processed ([@bib30], [@bib19]). Less than 4% of the samples did not meet this criterion and were discarded. Half of each sample was submitted to standard microbiological analysis (common microbiological culture and, in case of positive result, identification and antibody susceptibility test), while the remainder was stored at −80 °C for the molecular analysis. During April 2004--May 2005, a total of 510 consecutive lower tract respiratory samples (329 SP, 165 EA and 16 BAL), which were considered appropriate on the basis of microscope inspection, were analyzed.

The samples were thawed and liquefied by using 1:1 Sputasol (Oxoid Ltd., Basingstoke, England), and then underwent DNA/RNA extraction ([@bib6]). RNA was reverse transcribed with random primers with a Reverse Transcriptase Kit (Invitrogen, Milan, Italy). Control DNA ((-globin DNA) and RNA (MS2 phage genome) preparations were spiked into the samples before the extraction, to control their suitability for PCR/RT-PCR.

The molecular diagnostic panel included: FLU-A and -B, hMPV, AdV, PIV-1, -2 and -3, RSV, HRV, hCoV-OC43, -229E and -NL63. Specific primers and PCR or RT-PCR conditions were as previously described ([@bib1], [@bib34], [@bib11], [@bib21], [@bib2], [@bib37], [@bib27], [@bib15], [@bib4], [@bib12], [@bib41], [@bib28]). The sensitivity of the assays ranged between 1 and 10 copies for FLU-A, AdV, PIV-1, -2 and -3, RSV, HRV and hCoV-NL63; between 10 and 50 copies for FLU-B and hMPV A; and about 300 copies for hCoV-OC43. These sensitivity values, established by probit analysis on plasmids containing the target region as the insert, were confirmed by participation in the Quality Control for Molecular Diagnostics External Quality Assurance (QCMD EQA) programmes (Glasgow, UK). From the hMPV QCMD EQA programme MPV.RSV06, we determined that the sensitivity for hMPV B of our test was much lower (\>1000 times) than for other respiratory viruses.

The amplified products were separated by agarose gel electrophoresis and UV-visualized after ethidium bromide staining.

3. Results {#section0015}
==========

A molecular diagnostic panel for detection of 12 viruses was applied to 510 lower respiratory samples from 433 adult patients hospitalized with pulmonary diseases.

The most common respiratory illnesses in the patients were: COPD, 45.3%, pneumonia (30.5%) and acute respiratory illness (ARI, 17.1%); 19.6% of patients were in the intensive care unit, and 17.5% were receiving assisted ventilation ([Table 1](#tbl1){ref-type="table"} ). Two hundred and fifteen specimens (42.2%) were positive for a respiratory virus ([Table 2](#tbl2){ref-type="table"} ). The most common viruses were HRV (32.9%), FLU-A (9.0%) and hCoV-NL63 (2.0%). The frequency of the other viruses ranged from 0.2 to 1.4%. In 30 out of 510 samples (5.9%), corresponding to 29 out of 433 patients (6.7%), more than one virus was detected. Multiple detection included HRV + FLU-A (2.9% of total samples), HRV + FLU-B and HRV + hCoV-NL63 (0.6% each combination), HRV + hCoV-OC43 (0.4%), HRV + AdV, HRV + PIV-1, HRV + RSV, FLU-A + hCoV-OC43, AdV + hCoV-NL63, HRV + FLU-A + PIV-1 and HRV + FLU-A + AdV (0.2% each combination). The association with the sample type (either EA, or SP, or BAL) could be evaluated only for the most frequent viruses, i.e. FLU-A and HRV, showing that HRV, and not FLU-A, was unevenly distributed (more frequent in SP and BAL than in EA, [Table 2](#tbl2){ref-type="table"}). Data on the smoking status was available for 403/433 patients: the frequency of patients positive to any virus was similar in smokers and non-smokers (49.4% vs. 50.6%, *p*  = 0.742), and the frequency of individual viruses did not significantly differ according to the smoker status (for instance, HRV positive patients were 42.2% in smokers and 34.5% in non-smokers, *p*  = 0.137).Table 1Demographic and clinical characteristics of 433 adult hospitalized patientsAge Mean (±S.D.)56.3 (18.2) Median (IQR)57.0 (41--72)  Sex Male (%)291 (67.2) Female (%)136 (31.4) Not known (%)6 (1.4)  Smoking status Smokers (%)168 (38.8) Non-smokers (%)235 (54.3) Not known (%)30 (6.9)  Clinical findings COPD (%)196 (45.3) Pneumonia (%)132 (30.5) Acute respiratory failure (%)76 (17.5) Chronic respiratory failure (%)15 (3.5) Assisted ventilation (%)76 (17.5) Asthma (%)9 (2.1)[^1]Table 2Detection of respiratory agents in 510 samples from 433 adult hospitalized patientsRespiratory agentDistribution of positive specimens, *n* (%)Overall positivitySPEABALFLU-A[\*](#tbl2fn1){ref-type="table-fn"}46 (9.0)24 (7.3)20 (12.1)2 (12.5)FLU-B5 (1.0)5 (1.5)00PIV-16 (1.2)6 (1.8)00PIV-20000PIV-31 (0.2)01 (0.6)0RSV1 (0.2)1 (0.3)00hMPV0000HRV[\*\*](#tbl2fn2){ref-type="table-fn"}168 (32.9)124 (37.7)39 (23.6)5 (31.2)hCoV-OC437 (1.4)4 (1.2)3 (1.8)0hCoV-229E0000hCoV-NL6310 (2.0)7 (2.1)3 (1.8)0AdV6 (1.2)6 (1.8)00  Samples positive to at least 1 agent[\*\*\*](#tbl2fn3){ref-type="table-fn"}215 (42.2)156 (47.4)58 (35.1)6 (37.5)Samples positive to \>1 agent30 (5.9)22 (6.7)8 (4.8)0Total analyzed samples510 (100)329 (100)165 (100)16 (100)[^2][^3][^4][^5]

In addition, similar frequencies of virus**-**positive samples were obtained when comparing patients with COPD vs. patients without COPD (57.1% vs. 56.7%); patients with pneumonia vs. subjects with no record of pneumonia (54.4% in both cases); or patients with ARI vs. subjects without ARI (44.7% vs. 51.5%, *p*  = 0.342). In addition, the frequency of virus-positive samples did not significantly differ among patients with pneumonia, COPD and ARI (*p*  = 0.207).

The monthly distribution of respiratory agents over the study period ([Fig. 1](#fig1){ref-type="fig"} ) highlights a peak in January--February for HRV and FLU-A.Fig. 1Monthly distribution of lower respiratory tract samples positive for respiratory viruses, during April 2004--May 2005. The line represents the total collected samples, while the bars represent the samples positive for the indicated viruses. First panel: absolute numbers; lower panels: frequency (%) of samples positive for the indicated viruses.

4. Discussion {#section0020}
=============

Many reports have highlighted the possible role of viruses as causative agents, or as possible co-factors, in LRTIs. We applied a large molecular diagnostic panel which included 12 respiratory viruses to evaluate the prevalence of respiratory pathogens in adults hospitalized in Italy, during April 2004--May 2005. Although we would be unable to detect some viral respiratory pathogens, such as bocavirus, coronavirus HKU1 and parainfluenzavirus 4, this is the first extensive investigation of lower respiratory tract secretions from adults that was capable of detecting such a wide selection of respiratory pathogens. We have made the assumption that the samples represent the lower respiratory tract, as a recognized microscope inspection criterion was used to validate their quality. However, as expectorated sputum is necessarily contaminated with oral contents, it is not possible to rule out that the virus detected in the samples (mainly SP) could actually derive from contamination by upper respiratory tract secretions. In fact, the rate of positivity in SP is higher than in EA and BAL (47.4% vs. 35.1% and 37.5%, respectively); however, this is not the case for all viruses (i.e. FLU-A). In addition, the presence of several viruses (FLU-A, PIV-3, HRV, hCoV-OC43 and hCoV-NL63) on both EA and BAL, suggests that contamination with oral secretions is not a major source of the virus present in the analyzed samples.

Our results confirm previous data that HRV are the most frequent viruses in lower respiratory tract samples ([@bib18], [@bib35]), and strongly support the association of HRV with LRTIs, already hypothesized in previous studies based on upper respiratory samples ([@bib38]). However, based on the present data it is not possible to establish the precise role of HRV as a leading cause, as well as its possible involvement as co-factor in LRTIs.

Among the other viruses, accounting for 7.2% of positive samples, hCoV-NL63 was detected in 2.0% of samples. The involvement of hCoV (namely NL63) in lower respiratory diseases has been largely hypothesized, but available data are mostly based on upper respiratory samples, mostly on the basis of studies in pediatric patients ([@bib3], [@bib4], [@bib5], [@bib7], [@bib10], [@bib29], [@bib33]). The circulation of hCoV-NL63 in Italy is probably underreported. There is only one other report concerning this virus and lower respiratory samples from adults ([@bib20]).

We did not detect hMPV in our patients, although this is a relatively common respiratory pathogen ([@bib39], [@bib8]). The absence of hMPV is probably due to the low sensitivity of the RT-PCR assay used in this study (particularly for hMPV B). Alternatively, it is possible that sputasol, used to liquefy the samples, could have affected the sensitivity of the RT-PCR used. This issue could also apply to other viruses investigated in this study, such as RSV, and needs further investigation.

In conclusion, our study shows a high prevalence of viruses, especially HRV and influenza virus, in the lower respiratory tract samples of adult hospitalized patients with pulmonary diseases, without any significant difference in the frequency of virus-positivity among patients with pneumonia, COPD and ARI. Additional viruses were detected at low frequency. It is not possible to establish the role of viruses detected at low frequency as causative agents or as co-factors in LRTIs, but these results highlight the necessity to consider them as potential causes of LRTIs.
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[^1]: COPD, chronic obstructive pulmonary disease.

[^2]: SP, sputum; EA, endotracheal aspirate; BAL, bronchoalveolar lavage; FLU, influenzavirus; PIV, parainfluenzavirus; RSV, respiratory syncytial virus; hMPV, human metapneumovirus; HRV, human rhinovirus; hCoV, human coronavirus; AdV, adenovirus.

[^3]: *p* = 0.186.

[^4]: *p* = 0.007.

[^5]: *p* = 0.031 for frequency in SP, EA and BAL in *χ*^2^ test.
